Private Equity in Medical Devices: Strategies, Deals & Trends (2025-2026)
A deep dive into private equity's growing role in medtech — from Blackstone and TPG's landmark $18.3B Hologic take-private to buy-and-build platforms, CDMO acquisitions, the record Medline IPO exit, and PE dry powder deployment strategies.
Private Equity Is Reshaping Medtech
Private equity has transformed from a peripheral player in medical devices to one of the most powerful forces reshaping the industry. In 2025, PE-backed medtech deal value nearly doubled year-over-year to an estimated $33 billion, with deal volume increasing nearly 20% to roughly 88 transactions (Bain & Company Global Healthcare PE Report 2026).
A single deal dominated the year: Blackstone and TPG's $18.3 billion take-private of Hologic — accounting for more than half of all projected medtech PE buyout activity in 2025. But the Hologic deal was not an outlier. It was the culmination of a broader trend: PE firms deploying record dry powder into medtech assets that offer durable cash flows, regulatory moats, and operational improvement potential.
On the exit side, the Medline IPO at the end of 2025 raised $6.26 billion — the largest IPO globally that year and potentially the largest PE-backed IPO on record — validating the medtech PE thesis and demonstrating that the buy-improve-exit playbook works at massive scale.
The Landmark Deal: Hologic's $18.3 Billion Take-Private
Deal Structure
In October 2025, Blackstone and TPG announced a definitive agreement to acquire Hologic (Nasdaq: HOLX), a global leader in women's health diagnostics and medical imaging, in an all-cash transaction valued at up to $18.3 billion (Hologic Press Release).
| Detail | Value |
|---|---|
| Cash offer | $76 per share |
| Contingent Value Right (CVR) | Up to $3/share tied to breast health revenue milestones (FY2026-2027) |
| Total implied value | Up to $79 per share |
| Premium to pre-deal price | ~46% premium over pre-speculation trading price of ~$54 |
| Minority co-investors | Abu Dhabi Investment Authority (ADIA) and GIC (Singapore) |
| Debt financing | Citi, Bank of America, Barclays, Royal Bank of Canada, SMBC |
| Expected close | H1 2026 |
Sources: Hologic Press Release; LinkedIn (Global SWF analysis); MassDevice.
Why This Deal Matters
The Hologic take-private is the largest medical device acquisition since Boston Scientific's $27 billion purchase of Guidant Corp in 2006 — a nearly 20-year gap that underscores how significant the transaction is for the industry (ClearlyAcquired).
What attracted PE: Hologic's business combines several characteristics PE firms value most:
- Recurring revenue — Diagnostics and screening generate repeat consumable sales
- High margins — Breast health diagnostics is a high-margin, high-barrier-to-entry business
- Demographic tailwinds — Aging populations and expanding screening guidelines drive long-term volume growth
- Operational improvement potential — Hologic's share price had fallen roughly 24% in 2025 due to declining post-COVID diagnostic demand and tariff exposure, creating a favorable entry point (FT via MassDevice)
Strategic rationale: BTIG analyst Ryan Zimmerman noted: "We view this as generally positive for the medtech sector, as it adds to the pool of acquirers and could produce stronger businesses when they re-emerge as public assets" (LinkedIn/Surgical Robotics Technology).
Ram Jagannath, Senior Managing Director at Blackstone, stated: "Hologic is an outstanding global leader in advancing women's health, with a longstanding reputation for groundbreaking and high-quality medical device and diagnostic products" (Hologic Press Release).
The CVR Structure
The $3/share Contingent Value Right is tied to Hologic achieving specific global revenue milestones in its breast health business during FY2026-2027. Analysts viewed this as a sensible way to bridge the valuation gap — capping public shareholder upside near the offer price while shifting integration and financing execution risk to the PE sponsors (The Deal Desk, UTD GFMC Newsletter).
PE Strategies in Medtech: Four Playbooks
1. Large-Scale Take-Privates
The Hologic deal exemplifies the mega take-private strategy. PE firms target publicly traded medtech companies that are:
- Undervalued relative to intrinsic value (often due to temporary headwinds)
- Operationally complex with room for margin improvement
- Cash-flow generative with predictable recurring revenue
Other recent PE interest in public medtech includes approaches to Surmodics (under government scrutiny) and strategic investments in Henry Schein (MassDevice).
The Bain Global Healthcare PE Report 2026 confirms that investors are deploying "proven value-creation playbooks: focusing on revenue growth, margin expansion, and multiple expansion, while managing downside risk. This is especially true in large-scale assets that have origins in public markets, whether as take-privates or carve-outs."
2. Corporate Carve-Outs
PE firms are increasingly absorbing divisions that medtech conglomerates no longer want:
| Deal | PE Firm | Carve-Out From | Business | Approximate Value |
|---|---|---|---|---|
| Vantive | Carlyle Group | Baxter | Global renal care (~$4.5B revenue) | Multi-billion (undisclosed) |
| Emergency Care | Bridgefield Capital | Philips | Emergency care devices | Undisclosed |
| Business units | Various PE | Bioventus | Orthobiologics segments | Undisclosed |
The Carlyle/Vantive deal was one of the most notable carve-outs of the cycle, creating a standalone global renal care company from Baxter's underperforming division. According to the Bain report, this type of deal represents PE's growing appetite for "large-scale assets" from corporate parents seeking portfolio simplification (Bain Healthcare PE Report 2026).
3. Buy-and-Build Platforms
PE firms have become prolific builders of medtech platforms through serial acquisitions of smaller companies in fragmented segments:
CDMO and Contract Manufacturing Platforms:
- Montagu Private Equity created a med-tech CDMO platform by combining Tyber Medical, Intech, and Resolve Surgical Technologies (LinkedIn)
- Vance Street Capital has been assembling a medical component manufacturing platform, acquiring Injectech and partnering with MRPC for contract manufacturing (MPO Magazine)
- Medical Manufacturing Technologies (MMT) — PE-backed — executed a string of acquisitions in 2025: Innova Design, GenX Medical, and Comco, building a diversified medtech manufacturing platform (MPO Magazine)
- Quasar Medical acquired Nordson Medical's facilities in Ireland and Mexico, expanding its design and development capabilities (MPO Magazine)
Specialty Device Platforms:
- Innovia Medical acquired Grace Medical and Hurricane Medical to build a specialty surgical device platform
- Resonetics (PE-backed) acquired Medical Component Specialists to expand its gun drilling and precision machining capabilities
- Arterex acquired Adroit USA and Phoenix S.R.L. (Italy) to build a cross-border medical manufacturing platform (MPO Magazine)
The buy-and-build model works particularly well in medtech CDMO because the sector is highly fragmented, customers value one-stop-shop manufacturing partners, and there are significant economies of scale in quality systems, regulatory compliance, and facility utilization.
4. Growth Equity and Minority Investments
Beyond controlling buyouts, PE firms are making strategic minority investments in high-growth medtech companies:
- PE-backed investment in Henry Schein, the dental and medical distribution company (MassDevice)
- Sovereign wealth co-investments alongside PE, as seen with ADIA and GIC participating in the Hologic deal
- Growth equity investments in digital health and medtech software companies approaching IPO readiness
The Medline Exit: PE's Greatest Medtech Success Story
The Medline IPO at the end of 2025 stands as the most spectacular PE exit in medtech history.
The Numbers
| Metric | Value |
|---|---|
| IPO proceeds | $6.26 billion (upsized from initial $5.37B target) |
| IPO price | $29 per share (216 million shares) |
| Opening trade | $35 per share (+21% from IPO price) |
| First-day close | ~$41 per share (+41% from IPO price) |
| IPO valuation | $50+ billion |
| Original buyout (2021) | ~$34 billion (Blackstone, Carlyle, Hellman & Friedman, GIC) |
| PE equity invested | ~$3.5 billion |
| 2024 net sales | $25.5 billion |
Sources: Axios; FT; LinkedIn (PE Insights); TradingView; BioWorld.
What Made It Work
Operational transformation: Over four years of PE ownership, Medline executed more than $1 billion in acquisitions and significant international expansion. The company entered the IPO as the undisputed market leader in U.S. hospital supplies — too large for a trade sale and perfectly positioned for a public listing (Axios).
Debt reduction: Fitch expected a multi-notch credit rating upgrade for Medline following approximately $4 billion of post-IPO debt reduction, addressing the leverage from the 2021 buyout (TradingView).
Market timing: Medline's IPO was the largest US stock debut in four years and only the fifth US-listed firm to raise more than $5 billion in an IPO over the past decade — proving that the public markets have appetite for large-scale, PE-backed medtech listings (LinkedIn/PE Insights).
The founding Mills family remained Medline's largest single shareholder throughout the PE ownership period, providing continuity and alignment (Axios).
The Healthcare PE Landscape: 2025 in Numbers
According to the Bain & Company Global Healthcare PE Report 2026:
- Total healthcare PE deal value exceeded an estimated $191 billion in 2025 — surpassing the previous record set in 2021 and confirming a full return of large-scale healthcare dealmaking
- The Hologic deal alone represented about 9% of total healthcare PE deal value for the year
- Medtech PE deal value nearly doubled over the prior year to an estimated $33 billion
- Medtech PE deal volume increased nearly 20% to an estimated 88 deals
- PE dry powder remains at record levels across healthcare
- Exit activity showed signs of recovery, with the Medline IPO serving as a proof-of-concept for PE-backed medtech listings (the $6B+ IPO was not even included in Bain's 2025 exit statistics due to its late-year timing)
The report noted that PE investors view medtech as increasingly attractive because the sector offers "opportunities to deploy proven value-creation playbooks" with manageable downside risk — a contrast to higher-risk biopharma investments.
Risks and Challenges
Regulatory Scrutiny
PE-backed medtech deals face growing regulatory attention:
- The Surmodics sale to PE remains under government scrutiny, highlighting that antitrust concerns apply to PE transactions as well as strategic M&A (MassDevice)
- FTC has shown increased willingness to challenge healthcare deals under the current administration
- PE-backed companies that reduce R&D spending or cut quality systems to boost short-term margins can face FDA enforcement actions
Leverage Risk
The Hologic take-private involves approximately two-thirds debt financing, which is typical for large PE buyouts but creates execution risk if growth or margins underperform. In a higher interest rate environment, servicing acquisition debt becomes more expensive (ClearlyAcquired).
Tariff and Trade Exposure
PE-backed medtech companies face the same tariff risks as their publicly traded peers. Hologic's pre-deal stock decline was partly attributed to tariff exposure from manufacturing in China and Costa Rica (MassDevice/FT). PE firms must factor trade policy volatility into their operational improvement plans.
Quality and Safety Concerns
Critics argue that PE ownership can prioritize financial engineering over product quality and patient safety. However, the FDA's Quality System Regulation (now QMSR, aligned with ISO 13485) applies equally regardless of ownership structure, and PE firms generally understand that quality failures destroy value faster than operational improvements create it.
What This Means for Medtech Professionals
For Startup Founders
- PE firms are active acquirers at all stages. Buy-and-build platforms are constantly looking for bolt-on acquisitions in specific sub-segments.
- Understand PE valuation frameworks — PE buyers evaluate companies differently than strategic acquirers. They focus on EBITDA margins, growth trajectory, and operational improvement potential rather than strategic synergies alone.
- CDMO and contract manufacturing startups are particularly attractive to PE platforms seeking to consolidate fragmented markets.
For Corporate Development Teams
- PE firms are both competitors and partners — they compete for carve-out assets but can also serve as co-investors or exit partners.
- Reverse Morris Trust structures require careful planning but can save billions in taxes on divestitures.
- Monitor PE platform strategies to anticipate where consolidation pressure is building in your supply chain or competitive landscape.
For Regulatory Professionals
- Ownership changes require regulatory notifications in most major markets. Plan for 12-24 months of regulatory transition when a PE-backed restructuring occurs.
- Quality system integrity must be maintained through ownership transitions. Both FDA and EU Notified Bodies scrutinize quality system changes during corporate restructurings.
Outlook: What PE Will Do Next in Medtech
Based on current PE activity and dry powder levels, expect the following in 2026 and beyond:
- More take-privates — Mid-cap medtech companies trading at depressed valuations (especially those hit by tariff concerns) are natural targets
- More CDMO platform building — The medtech CDMO space remains highly fragmented with significant consolidation runway
- More carve-out acquisitions — As medtech conglomerates continue divesting, PE firms will absorb the spun-off units
- Healthcare services adjacent to devices — PE firms are expanding into surgical centers, outpatient imaging, and device-related services
- Medline-style IPO exits — The Medline success will encourage PE firms to pursue public listings for their largest medtech portfolio companies
The Hologic take-private and Medline IPO bracket the full PE lifecycle in medtech: buy undervalued assets, improve operations, and exit at a premium. With record dry powder and a proven playbook, PE's influence on the medical device industry will only grow.
Key Takeaways
- PE medtech deal value nearly doubled in 2025 to ~$33B, with the Hologic take-private ($18.3B) accounting for more than half
- Blackstone and TPG's Hologic acquisition is the largest medtech deal since 2006, structured with a $3/share CVR to bridge valuation risk
- The Medline IPO ($6.26B raised, $50B+ valuation, 41% first-day pop) is the most successful PE medtech exit in history
- Buy-and-build platforms in CDMO and contract manufacturing are proliferating as PE firms consolidate fragmented segments
- Corporate carve-outs (Carlyle/Vantive, Bridgefield/Philips) are creating new PE-backed medtech companies at scale
Sources: Bain & Company Global Healthcare PE Report 2026; Hologic Press Release; Blackstone; TPG; MassDevice; ClearlyAcquired; Axios; FT; LinkedIn (PE Insights, Global SWF, Surgical Robotics Technology); TradingView; BioWorld; MD+DI; MPO Magazine; MedTech Dive; The Deal Desk (UTD GFMC).